Tag Archives: Lyft

Financial Daily Dose 6.25.2019 | Top Story: Allergan and AbbVie Combine Forces in $63 Billion Deal

BY: Michael D. Reif | June 25, 2019

Massive pharma news to start the day, with AbbVie announcing that it’s reached a deal to buy Allergan for roughly $63 billion. The tie-up is seen as giving AbbVie a “dominant position in the $8 billion-plus market for Botox and other beauty drugs” is it “braces for the end of patent protection for the world’s … Continue reading

Financial Daily Dose 5.8.2019 | Top Story: US/China Trade Talks Resume

BY: Michael D. Reif | May 8, 2019

China’s lead trade negotiator, Vice Premier Liu He, is in D.C. today—despite the White House’s latest threats to increase tariffs by 15% on $200 billion of Chinese goods—to continue trade talks with his U.S. counterparts. Mr. Liu’s personal involvement in the negotiations had been up in the air earlier in the week because of the … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | April 2, 2019

Just months after Whole Foods raised prices on certain items after an initial Amazon-pushed lowering, Bezos & Co. are planning cuts on “hundreds of items” as early as this week in an effort to “change the chain’s high-cost image amid intense competition among grocers” – WSJ and Bloomberg While the political saga that is Brexit … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | April 1, 2019

Lyft had a banner debut on the public markets, with its shares jumping 8.7% “after opening at $87.24, far above the public offering price of $72.” Some analysts are interpreting the strong showing as a sign that the gig economy is now officially part of the economic prime time – NYTimes and WSJ and Bloomberg … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | December 7, 2018

Jobs Report Friday again. Here’s what you should have in mind as you peruse the numbers – Bloomberg and WSJ and NYTimes Despite what are expected to be “very strong” figures, the Federal Reserve is reportedly considering a new “wait-and-see mentality after a likely interest-rate increase at their meeting in December.” This “data dependent” strategy … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | October 17, 2018

In order to comply with European antitrust rulings against it earlier this year, Google announced that for the first time it will begin charging telephone handset manufacturers to install Gmail, Google Maps, and other popular Android apps within the EU – NYTimes and WSJ Uber, still working on its forthcoming IPO, is reportedly focused on … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | October 20, 2017

Lyft, armed with a fresh billion from Google’s venture investment arm (CapitalG), is looking seriously at a 2018 IPO. The CapG money raises Lyft’s valuation from $6.9 billion to more than $10 billion – NYTimes and WSJ and Bloomberg Stitch Fix, on the other hand, isn’t waiting. The “fashion in a box” e-commerce company filed … Continue reading

Your Daily Dose of Financial News

BY: Michael D. Reif | September 15, 2017

Uber’s Softbank dilemma: is the $10 billion shot in the arm worth the price tag of roughly 30%? – WSJ Alphabet, meanwhile, is reportedly in talks to drop about $1 billion [leave it to Masayoshi Son to make that amount seem small] on Uber-rival Lyft – WSJ and Bloomberg The CFPB issued a no-action letter … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | August 22, 2016

Pfizer’s reportedly reached an agreement to purchase Medivation—a biotech firm known for its prostate-cancer drug Xtandi—in what’s anticipated to be a $14 billion deal – WSJ and Bloomberg Valeant’s hiring Zoetis’ Paul Herendeen as its new CFO as part of a continued effort to get back on track under the watchful eye of Bill Ackman … Continue reading

Your daily dose of financial news

BY: Michael D. Reif | August 16, 2016

ValueAct Capital Mgmt, an activist investor, has taken a $1.1 billion stake in Morgan Stanley with 38 million shares that represent about 2% of shares outstanding. Unlike normal activists (at least for now), ValueAct took the stake not to push for changes at the company but because it believes the market has undervalued Morgan Stanley … Continue reading